Previous 10 | Next 10 |
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
MARLBOROUGH, Mass. , June 8, 2020 /PRNewsire/ – Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today an...
Edwards Lifesciences (NYSE: EW ) -66% . More news on: Edwards Lifesciences Corporation, Iterum Therapeutics plc, Novus Therapeutics, Inc., Stocks on the move, , Read more ...
Gainers: Sonoma Pharmaceuticals (NASDAQ: SNOA ) +145% . More news on: Sonoma Pharmaceuticals, Inc., Adaptimmune Therapeutics plc, Phio Pharmaceuticals Corp., Stocks on the move, , Read more ...
Sonoma Pharmaceuticals (NASDAQ: SNOA ) +162% on COVID-19 nod in Australia for disinfectant. More news on: Sonoma Pharmaceuticals, Inc., Phio Pharmaceuticals Corp., Adaptimmune Therapeutics plc, Stocks on the move, , Read more ...
Phio Pharmaceuticals (NASDAQ: PHIO ) is up 14% premarket after announcing positive data from in vivo studies that show strong antitumoral efficacy with several of its INTASYL pipeline programs, including PH-762, PH-894 and PH-804. More news on: Phio Pharmaceuticals Corp., H...
MARLBOROUGH, Mass. , May 29, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced positiv...
MARLBOROUGH, Mass. , May 14, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL ™ ) therapeutic platform, today announced data ...
MARLBOROUGH, Mass. , May 12, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today reported its...
CPS Technologies (NASDAQ: CPSH ) +71% on Q1 results . More news on: CPS Technologies Corporation, Medigus Ltd., Predictive Oncology Inc., Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Phio Pharmaceuticals Corp. Company Name:
PHIO Stock Symbol:
NASDAQ Market:
Phio Pharmaceuticals Corp. Website:
Marlborough, Massachusetts--(Newsfile Corp. - July 12, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) (the "Company"), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells...
Five sites across the U.S. are now participating in the Phase 1b study Marlborough, Massachusetts--(Newsfile Corp. - July 8, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to ...
Marlborough, Massachusetts--(Newsfile Corp. - July 5, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced i...